Study of an antidote for severe side effects from fluoropyrimidine chemotherapy
Part of Cancer clinical trials.
This study tests an experimental antidote to help people who have had severe side effects or an overdose from common chemotherapy drugs called fluoropyrimidines (like 5-FU or capecitabine). The goal is to find the best dose and see if it can reduce the severity of these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be currently receiving a chemotherapy drug called a fluoropyrimidine (like 5-FU or capecitabine) for a solid tumor (not a blood cancer).
- You must have had a severe side effect (grade 3 or 4) or an overdose from this drug, such as severe nausea, diarrhea, low blood counts, or mouth sores.
- You must not be able to get the standard rescue medicine (uridine triacetate) for this toxicity.
- You must be able to take medicines by mouth and be willing to avoid alcohol during the treatment period.
- Your liver and kidney function must be within acceptable limits, and you must not have cirrhosis or severe kidney disease.
- You must be willing to use highly effective birth control (if you or your partner can become pregnant) and avoid sperm donation for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
This study tests a new combination therapy for people with advanced tumors that have not responded to other treatments. The goal is to see if the combination can shrink tumors and improve well-being.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
This study looks at whether people with solid tumors who develop heart-related side effects during a fluoropyrimidine chemotherapy can safely switch to a different fluoropyrimidine. It aims to see if the new option is feasible to use again when the first one caused cardiotoxicity.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.